Immune Checkpoint Inhibitors in Geriatric Oncology.

Autor: Cook SL; Department of Neurosurgery, Duke University School of Medicine, 047 Baker House, Trent Drive, Durham, NC, 27710, USA., Al Amin M; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.; Sher-E-Bangla Medical College, Barisal City, Bangladesh., Bari S; Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Poonnen PJ; Department of Veterans Affairs, Durham VA Medical Center, Durham, NC, USA.; Department of Veterans Affairs, National TeleOncology Program, Durham, NC, USA., Khasraw M; Department of Medicine, Duke University School of Medicine, Durham, NC, USA. mustafa.khasraw@duke.edu.; Department of Neurosurgery, Duke University School of Medicine, 047 Baker House, Trent Drive, Durham, NC, 27710, USA. mustafa.khasraw@duke.edu., Johnson MO; Department of Neurosurgery, Duke University School of Medicine, 047 Baker House, Trent Drive, Durham, NC, 27710, USA.; Department of Veterans Affairs, National TeleOncology Program, Durham, NC, USA.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2024 May; Vol. 26 (5), pp. 562-572. Date of Electronic Publication: 2024 Apr 08.
DOI: 10.1007/s11912-024-01528-3
Abstrakt: Purpose of Review: This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging.
Recent Findings: ICIs have led to significant advancements in the treatment of cancer. Landmark trials of ICIs have cited the efficacy and toxicity experienced by older patients, but most trials are not specifically designed to address outcomes in older patients. Underlying mechanisms of aging, like cellular senescence, affect the immune system and may ultimately alter the host's response to ICIs. Validated tools are currently used to identify older adults who may be at greater risk of developing complications from their cancer treatment. We review changes in the aging immune system that may alter responses to ICIs, report outcomes and toxicities in older adults from recent ICI clinical trials, and discuss clinical tools specific to older patients with cancer.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: